Hematologic malignancies following immune checkpoint inhibition for solid tumors

被引：6

作者：

van Eijs, Mick J. M. ^{[1
,2
]}

van der Wagen, Lotte E. ^{[3
]}

Mous, Rogier ^{[3
]}

Leguit, Roos J. ^{[4
]}

van de Corput, Lisette ^{[5
]}

van Lindert, Anne S. R. ^{[6
]}

Suelmann, Britt B. M. ^{[1
]}

Kamphuis, Anna M. ^{[1
]}

Nierkens, Stefan ^{[2
,7
]}

Suijkerbuijk, Karijn P. M. ^{[1
]}

机构：

[1] Univ Med Ctr Utrecht, Dept Med Oncol, POB 85500, NL-3508 GA Utrecht, Netherlands

[2] Univ Med Ctr Utrecht, Ctr Translat Immunol, Utrecht, Netherlands

[3] Univ Med Ctr Utrecht, Dept Hematol, Utrecht, Netherlands

[4] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands

[5] Univ Med Ctr Utrecht, Cent Diagnost Lab, Utrecht, Netherlands

[6] Univ Med Ctr Utrecht, Dept Pulmonol, Utrecht, Netherlands

[7] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands

来源：

CANCER IMMUNOLOGY IMMUNOTHERAPY | 2023年 / 72卷 / 01期

关键词：

Case series; Immune checkpoint inhibitor; Leukemia; Myeloid neoplasms; Second primary cancer; INTRINSIC PD-1 RECEPTOR; BLOCKADE; CANCER; SUPPRESSOR; EXPRESSION; RISK;

D O I：

10.1007/s00262-022-03230-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoint inhibition (ICI) can induce durable responses in patients with advanced malignancies. Three cases of hematological neoplasia following ICI for solid tumors have been reported to date. We present five patients treated at our tertiary referral center between 2017 and 2021 who developed chronic myeloid leukemia (two patients), acute myeloid leukemia, myelodysplastic syndrome and chronic eosinophilic leukemia during or after anti-PD-1-based treatment. Molecular analyses were performed on pre-ICI samples to identify baseline variants in myeloid genes. We hypothesize that PD-1 blockade might accelerate progression to overt myeloid malignancies and discuss potential underlying mechanisms.

引用

页码：249 / 255

页数：7

共 50 条

[1] Hematologic malignancies following immune checkpoint inhibition for solid tumors
Mick J. M. van Eijs
Lotte E. van der Wagen
Rogier Mous
Roos J. Leguit
Lisette van de Corput
Anne S. R. van Lindert
Britt B. M. Suelmann
Anna M. Kamphuis
Stefan Nierkens
Karijn P. M. Suijkerbuijk
Cancer Immunology, Immunotherapy, 2023, 72 : 249 - 255
[2] Checkpoint inhibition in hematologic malignancies
Tsumura, Aaron
Levis, Daniel
Tuscano, Joseph M.
FRONTIERS IN ONCOLOGY, 2023, 13
[3] Immune checkpoint blockade in hematologic malignancies
Armand, Philippe
BLOOD, 2015, 125 (22) : 3393 - 3400
[4] Editorial: Checkpoint inhibition in hematologic malignancies
Pu, Jeffrey J.
Drabick, Joseph J.
Prockop, Susan E.
FRONTIERS IN ONCOLOGY, 2024, 14
[5] Biomarkers for checkpoint inhibition in hematologic malignancies
Atanackovic, Djordje
Luetkens, Tim
SEMINARS IN CANCER BIOLOGY, 2018, 52 : 198 - 206
[6] Checkpoint inhibition in pediatric hematologic malignancies
Davis, Kara L.
Agarwal, Archana M.
Verma, Anupam R.
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2017, 34 (6-7) : 379 - 394
[7] The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies
Keung, Emily Z.
Wargo, Jennifer A.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2019, 28 (03) : 369 - +
[8] The influence of hematologic malignancies on response to immune checkpoint inhibition in patients with advanced melanoma
van Not, O. J.
Van Den Eertwegh, F.
Haanen, J. B. A. G.
van Rijn, R. S.
Aarts, M.
Van den Berkmortel, F.
Blank, C. U.
Boers-Sonderen, M.
de Groot, J. W. B.
Hospers, G.
Kapiteijn, E.
De Meza, M. M.
Piersma, D.
Stevense-den Boer, M.
Van der Veldt, A. A. M.
Vreugdenhil, G.
Wouters, M.
Blokx, W. A. M.
Suijkerbuijk, K. P. M.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S942 - S943
[9] Programming the immune checkpoint to treat hematologic malignancies
Vick, Eric
Mahadevan, Daruka
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (07) : 755 - 770
[10] Efficacy and Safety of Immune Checkpoint Inhibitors in Hematologic Malignancies
Bilgihan, Muhammed Talha
Eryigit, Ayse Nur
Ciftciler, Rafiye
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (01): : 23 - 31

← 1 2 3 4 5 →